Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/20576
Title: | Long-term antibody persistence after vaccination with a 2-dose Havrix (TM) (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions | Authors: | Theeten, Heidi Van Herck, Koen Van Der Meeren, Olivier Crasta, Priya Van Damme, Pierre HENS, Niel |
Issue Date: | 2015 | Publisher: | ELSEVIER SCI LTD | Source: | Vaccine, 33 (42), p. 5723-5727 | Abstract: | Antibody persistence in two cohorts of adults, who received inactivated hepatitis A (HAV) vaccine (1440El.U; Havrix (TM); GSK Vaccines) according to a 0-6 or 0-12 month schedule in 1992-1993, has been measured annually. After 20 years, >97% of the subjects in both studies were seropositive for anti-HAV antibodies. Geometric mean concentrations in the according-to-protocol cohorts were 312 mIU/ml in 34/36 subjects vaccinated initially at 0-6 months (NCT00289757) and 317 mIU/ml in 85/86 subjects vaccinated at 0-12 months (NCT00291876). Over the whole follow-up period, seven subjects (2 + 5, respectively) lost circulating anti-HAV antibodies but mounted a strong response after HAV booster administration (1440El.U). Mathematical modelling, which was applied to assess true persistence at Year 20 (accounting for drop-outs and missing data), and to predict longer-term persistence confirmed previous estimates that seropositive anti-HAV levels would persist in >= 95% vaccinees at Year 30 and >= 90% at Year 40. (C) 2015 Elsevier Ltd. | Notes: | [Theeten, Heidi; Van Hercka, Koen; Van Damme, Pierre; Hens, Niel] Univ Antwerp, Vaccine & Infect Dis Inst, B-2020 Antwerp, Belgium. [Van Hercka, Koen] Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium. [Van Der Meeren, Olivier; Crasta, Priya] Belgium & Mumbai, GlaxoSmithKline Wavre, Bombay, Maharashtra, India. [Hens, Niel] Hasselt Univ, Interunivers Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium. | Keywords: | immunogenicity; inactivated hepatitis A vaccine; long-term follow-up; mathematical modelling;Immunogenicity; Inactivated hepatitis A vaccine; Long-term follow-up; Mathematical modelling | Document URI: | http://hdl.handle.net/1942/20576 | ISSN: | 0264-410X | e-ISSN: | 1873-2518 | DOI: | 10.1016/j.vaccine.2015.07.008 | ISI #: | 000364268500035 | Rights: | © 2015 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2016 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
theeten 1.pdf | Published version | 1.27 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
36
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
63
checked on Sep 27, 2024
Page view(s)
58
checked on Sep 7, 2022
Download(s)
108
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.